Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
In clinical practice, whether FISH for EGR1 in interphase nuclei has similar efficacy to detect deletion 5q anomalies as conventional cytogenetic studies is unknown. We compared conventional cytogenetics and FISH for 145 patients with deletion 5q and detected this anomaly by both methods in 144. Nine patients with myelodysplasia were studied before and after treatment with Lenalidomide and results were concordant for 28 of 29 specimens. FISH did not detect anomalies other than deletion 5q in 31 patients. This study suggests FISH is useful to detect deletion 5q, but is not a substitute for conventional cytogenetics.
Zou
Ying S
YS
Cytogenetics and Hematology, Mayo Clinic, Rochester, MN 55905, USA.
Fink
Stephanie R
SR
Stockero
Kimberly J
KJ
Paternoster
Sarah F
SF
Smoley
Stephanie A
SA
Tun
Han W
HW
Reeder
Craig B
CB
Tefferi
Ayalew
A
Dewald
Gordon W
GW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002895:Chromosomes, Human, Pair 5; D020732:Cytogenetic Analysis; D015342:DNA Probes; D051766:Early Growth Response Protein 1 / Q000235:genetics*; D005260:Female; D017353:Gene Deletion; D006402:Hematologic Diseases / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015342:DNA Probes; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; D013792:Thalidomide; D000077269:Lenalidomide